Jefferies initiated coverage of Stoke Therapeutics (STOK) with a Buy rating and $30 price target The firm likes the stock’s risk/reward into zorevunersen’s Phase III data for Dravet syndrome in the second half of 2027. The trial has a 40%-50% chance of producing differentiated efficacy, potentially opening up a $1B-$1.5B opportunity for Stoke, the analyst tells investors in a research note. Jefferies is looking forward to a potential “material update” from an FDA meeting in the second half of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome
- Buy Rating for Stoke Therapeutics: Promising Dravet Syndrome Treatment Shows Significant Improvements
- Stoke Therapeutics, Biogen present data from EMPEROR study
- Biogen, Stoke Therapeutics present data from studies of zorevunersen
- Stoke Therapeutics files $400M mixed securities shelf